Prevalence of Malignancy and Chronic Obstructive Pulmonary Disease among Patients with COVID-19: A Systematic Review and Meta-analysis

Document Type : Review Article


1 Department of Internal Medicine, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Medical Center of Digestive Disease, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

3 School of Medicine, Capital Medical University, Beijing, China

4 Department of Internal Medicine, School of Medicine, Bandarabbas University of Medical Sciences, Hormozgan, Iran

5 Department of Cardiology, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran


Background and aim: Prevalence malignancy and COPD in the patients infected by COVID-19 has been considered to be of high importance for the health-care laborers. Therefore, the present systematic review and meta-analysis aimed to determine the malignancy prevalence and the chronic obstructive pulmonary disease amongst COVID-19 patients.
Materials and methods: Some electronic databases, PubMed, Cochrane Library, Embase, and ISI have been used to perform systematic literature in May 2020. Then, a software program (Endnote X8) has been utilized for managing the electronic titles. Two reviewers blind and independently extracted data from abstracts and full-text studies. Moreover, the prevalence of malignancies and COPD with 95% CI has been estimated via the inverse variance method and fix effect model of meta-analysis. Also, heterogeneity has been assessed with I2 and Chi-square. Consequently, forest plots and Funnel plot have been evaluated with the use of a software program (i.e., Comprehensive Meta-Analysis Stata V16).
Results: A total of 167 potentially relevant titles and abstracts have been found during the electronic and manual search. Finally, ten studies have been included. Prevalence of Malignancy equalled 1.56%, effect size has been (ES 2.04 95% CI -61.03, 65.11. P= 0.95) among the six studies and the total number of patients has been 1595 (915 men, 680 female) with the age range of 20-68 years. No statistically significant difference has been found between studies (p=1.00).

Conclusion: It has been found that malignancy and chronic obstructive pulmonary disease are the most pervasive underlying diseases in patients with COVID-19.


Main Subjects

[1]  Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
[2]  Thompson R. Pandemic potential of 2019-nCoV. The Lancet Infectious Diseases. 2020;20(3):280. S1473-3099(20)30068-2.
[3]  Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, evaluation and treatment coronavirus (COVID-19). InStatpearls [internet]: StatPearls Publishing; 2020.
[4]  Borges do Nascimento IJ, Cacic N, Abdulazeem HM, von Groote TC, Jayarajah U, Weerasekara I, Esfahani MA, Civile VT, Marusic A, Jeroncic A, Carvas Junior N. Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis. Journal of clinical medicine. 2020;9(4):941.
[5]  Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, Haagmans BL, Lauber C, Leontovich AM, Neuman BW. Severe acute respiratory syndrome-related coronavirus: The species and its viruses–a statement of the Coronavirus Study Group. bioRxiv 2020. DOI. 2020;10(2020.02):07-937862.
[6]  COVID C. global cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). ArcGIS. Johns Hopkins CSSE. Retrieved April. 19;8:2020.
[7]  Restrepo MI, Mortensen EM, Pugh JA, Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. European Respiratory Journal. 2006;28(2):346-51. DOI: 10.1183/09031936.06.00131905.
[8]  Restrepo MI, Sibila O, Anzueto A. Pneumonia in patients with chronic obstructive pulmonary disease. Tuberculosis and respiratory diseases. 2018;81(3):187-97.
[9]  Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. Journal of virology. 2020;94(7). DOI: 10.1128/JVI.00127-20.
[10]Penn I. Malignancy. Surgical Clinics of North America. 1994;74(5):1247-57.
[11] Yahalom J, Dabaja BS, Ricardi U, Ng A, Mikhaeel NG, Vogelius IR, Illidge T, Qi S, Wirth A, Specht L. ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. blood. 2020;135(21):1829-32.
[12] Bai X, Fang C, Zhou Y, Bai S, Liu Z, Xia L, Chen Q, Xu Y, Xia T, Gong S, Xie X, et al. Predicting COVID-19 malignant progression with AI techniques. 2020.
[13] Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement (Chinese edition). Journal of Chinese Integrative Medicine. 2009;7(9):889-96.
[14] Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25(9):603-5.
[15] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DS, Du B, et al. Clinical characteristics of coronavirus disease 2019 in China. New England journal of medicine. 2020;382(18):1708-20. DOI: 10.1056/NEJMoa2002032.
[16] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020.
[17] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Yu T. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-13.
[18] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH, Li GC. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese medical journal. 2020. doi: 10.1097/CM9.0000000000000744.
[19] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9. doi:10.1001/jama.2020.1585.
[20] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. bmj. 2020 Feb 19;368.
[21] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020.
[22] Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, Wei S, Deng Y, Liu J, Liu HG, Ming Y, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese medical journal. 2020. doi: 10.1097/CM9.0000000000000775.
[23] Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, Wang Z, Li J, Li J, Feng C, Zhang Z, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020;63(3):364-74.
[24] Khan N, Fahad S. Critical review of the present situation of corona virus in China. Available at SSRN 3543177. 2020.
[25] Seys LJ, Widagdo W, Verhamme FM, Kleinjan A, Janssens W, Joos GF, Bracke KR, Haagmans BL, Brusselle GG. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clinical Infectious Diseases. 2018;66(1):45-53.
[26] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020.
[27] Li J, Long X, Luo H, Fang F, Lv X, Zhang D, Sun Y, Luo F, Li N, Zhang Q, Fang X. Clinical characteristics of deceased patients infected with SARS-Cov-2 in Wuhan, China. 2020.
[28] Xia Y, Jin R, Zhao J, Li W, Shen H. Risk of COVID-19 for cancer patients. Lancet Oncol. 2020;21(4). DOI:10.1101/2020.02.06.20020974.
[29] Kotecha RS. Challenges posed by COVID-19 to children with cancer. The Lancet Oncology. 2020;21(5):e235. DOI:
[30] Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020;21(3):335-7.DOI:
[31] Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: a systematic review and meta-analysis. Archives of academic emergency medicine. 2020;8(1).
[32] Favre G, Pomar L, Musso D, Baud D. 2019-nCoV epidemic: what about pregnancies?. Lancet (London, England). 2020;395(10224):e40. doi: 10.1016/S0140-6736(20)30311-1.
[33] Schwartz DA, Graham AL. Potential maternal and infant outcomes from (Wuhan) coronavirus 2019-nCoV infecting pregnant women: lessons from SARS, MERS, and other human coronavirus infections. Viruses. 2020;12(2):194.
[34] Lin HT, Xiang YF, Cui TX, Chen JJ. Online learning-related visual impairment and preventive measures during the 2019 novel coronvirus outbreak. [Zhonghua yan ke za zhi] Chinese journal of ophthalmology. 2020;56:E004.
Volume 2, Issue 2
June 2020
Pages 52-58
  • Receive Date: 11 April 2020
  • Revise Date: 30 May 2020
  • Accept Date: 09 June 2020
  • First Publish Date: 17 June 2020